Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pfizer ( (PFE) ) has shared an update.
Pfizer shareholders held their Annual Meeting on April 23, 2026, where they re-elected the full slate of board nominees, including Chief Executive Albert Bourla and other incumbent directors, for terms lasting until the next annual meeting. Investors also strongly backed the ratification of KPMG LLP as the independent auditor for the 2026 fiscal year, reinforcing continuity in the company’s financial oversight.
Shareholders approved an amendment to the Pfizer Inc. 2019 Stock Plan and gave advisory support to the 2026 compensation package for the company’s named executive officers, signaling broad endorsement of Pfizer’s current executive pay and incentive structures. A shareholder proposal to require an independent board chair failed to pass, indicating continued investor acceptance of the combined chair and CEO structure and preserving the existing governance framework.
The most recent analyst rating on (PFE) stock is a Sell with a $25.00 price target. To see the full list of analyst forecasts on Pfizer stock, see the PFE Stock Forecast page.
Spark’s Take on PFE Stock
According to Spark, TipRanks’ AI Analyst, PFE is a Neutral.
The score is primarily constrained by only mid-level financial performance (volatile revenues, lower cash flow than prior peaks, and elevated leverage). Offsetting this, technicals are constructive with price above key moving averages and positive MACD, and shareholder yield is attractive. Earnings-call commentary is moderately positive on guidance and productivity/pipeline progress, but tempered by COVID and LOE headwinds plus GAAP volatility.
To see Spark’s full report on PFE stock, click here.
More about Pfizer
Pfizer Inc. is a global pharmaceutical company that develops, manufactures, and markets prescription medicines and vaccines. The company focuses on innovative treatments across a range of therapeutic areas, including infectious diseases, oncology, and chronic conditions, serving healthcare systems and patients worldwide.
Average Trading Volume: 41,241,320
Technical Sentiment Signal: Buy
Current Market Cap: $153.6B
See more data about PFE stock on TipRanks’ Stock Analysis page.